Gilead Sciences Presents Three-year Outcomes From BICSTaR Study With Biktarvy

(RTTNews) - Gilead Sciences, Inc. (GILD) reported new long-term real-world data from the BICSTaR study highlighting the safety and efficacy profile of Biktarvy as a treatment regimen for a broad range of people with HIV, including those with a prior treatment history or comorbidities. Overall, Biktarvy was found to be highly effective for trial participants after three years of follow-up, with 97% of treatment-nave and 97% of treatment-experienced participants virologically suppressed.

"The results complement the results observed in multiple Phase 3 clinical trials, which demonstrate the sustained efficacy, safety profile, and high barrier to resistance of Biktarvy," said Fernando Bognar, Vice President of Global Medical Affairs for HIV at Gilead Sciences.

For More Such Health News, visit rttnews.com.